<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753154</url>
  </required_header>
  <id_info>
    <org_study_id>PD-NL-04-EU</org_study_id>
    <nct_id>NCT01753154</nct_id>
  </id_info>
  <brief_title>The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis</brief_title>
  <official_title>The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the biocompatibility of the peritoneal dialysis (PD) solution balance in
      comparison to the conventional PD solution in APD(automated peritoneal dialysis) patients
      using the APD cycler sleep•safe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Equivalence of the investigational PD solution balance regarding fluid status compared to the
      conventional PD solution.

      Effects of balance on inflammation and systemic advanced glycation end products formation.

      Effects of balance on peritoneal and total urea clearance, on peritoneal and total creatinine
      clearance and on ultrafiltration, on residual diuresis and on cholesterol levels.

      Safety of the investigational PD solution balance and the conventional PD solution as a
      control drug.

      The mesothelial cell mass assessed by Cancer Antigen 125 is affected by the use of the type
      of PD solution in APD patients using sleep•safe. Treating patients with the PD solution
      balance leads to not more than 1 litre difference in hydration in comparison to the
      conventional PD solution which is considered as clinically not relevant regarding blood
      pressure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CA 125 (cancer antigen 125) appearance rate in the 24 hours effluent and estimated hydration</measure>
    <time_frame>16 weeks</time_frame>
    <description>The appearance rate is defined as the sum of the amount of CA125 determined in each outflow bag (concentration of CA125 in outflow multiplied with outflow volume) divided by the real cumulative dwell time of all dwells performed on the day of the 24-hour dialysate collection.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Solution B (balance PD solution)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 8 weeks with solution B (balance PD solution), next 8 weeks with solution A (conventional PD solution)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solution A (conventional PD solution)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment 8 weeks with solution A (conventional PD solution), next 8 weeks with solution B (balance PD solution)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solution B (balance PD solution)</intervention_name>
    <description>balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium</description>
    <arm_group_label>Solution B (balance PD solution)</arm_group_label>
    <other_name>Balance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solution A (conventional PD solution)</intervention_name>
    <description>Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)</description>
    <arm_group_label>Solution A (conventional PD solution)</arm_group_label>
    <other_name>CAPD 2, CAPD 3, CAPD 4, CAPD 17, CAPD 18 and CAPD 19</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  APD patient ≥ 18 years

          -  Prevalent patient with at least 3 months experience on APD prior to inclusion

          -  Patient is trained on and being treated with the sleep•safe APD cycler

          -  Patient treated on APD exclusively with registered conventional PD solutions CAPD 2,
             CAPD 3, CAPD 4, CAPD 17, CAPD 18 or CAPD 19 for at least 8 weeks prior to inclusion

          -  Patient is on stable diuretic treatment e.g no change in diuretic treatment within the
             last 30 days prior to inclusion

          -  Informed consent signed and dated by study patient and investigator/authorised
             physician

          -  Ability to understand the nature and requirements of the study

        Exclusion Criteria:

          -  Peritonitis treatment £ 4 weeks preceding inclusion

          -  APD patients treated with IPD modality (intermittent peritoneal dialysis)

          -  Malignant disease without remission

          -  Patients with artificial joints, amputations, stents, or pacemaker

          -  Patients with congestive heart failure or coronary artery disease NYHA (New York Heart
             Association) III and higher

          -  Active HBV (hepatitis B virus)or HCV(hepatitis C virus)infection- HIV positive

          -  Participation in an interventional clinical study during the preceding 30 days

          -  Any condition which could interfere with the patient's ability to comply with the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariano Feriani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Umberto Oo, 30174 Mestre, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centrum Dializ Fresenius Nephrocare</name>
      <address>
        <city>Gdańsk,</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny nr 1</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo hospitalario universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Hospital Alcorcón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2012</study_first_submitted>
  <study_first_submitted_qc>December 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2012</study_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>Biocompatible dialysis solution</keyword>
  <keyword>Hydration status</keyword>
  <keyword>Residual renal function</keyword>
  <keyword>Body composition monitor</keyword>
  <keyword>Bioimpedance spectroscopy</keyword>
  <keyword>Cancer antigen 125</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

